Technology Focus

Fixing the antisense story

While investors in Isis Pharmaceuticals Inc. may have been looking to the company's ISIS 2302 compound to treat Crohn's disease as the final validation of antisense, the failure of ISIP's pivotal study does not mean that antisense on the whole does not work. Antisense, say proponents, faces no more complex issues than do other biotherapeutics and appears to be just as broadly applicable.

The question now is whether investors will give them the chance to prove it. Although ISIP already is marketing its